{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:24:51Z","timestamp":1725063891846},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"DOI":"10.7759\/cureus.68217","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T15:44:39Z","timestamp":1725032679000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Recurrence-Free Survival of an Elderly Patient With Diffuse Large B-cell Lymphoma in the Setting of Rituximab-Containing Therapy and a Natural History of Gastric Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Toshiyuki","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0039-7","article-title":"Commentary on the WHO Classification of Tumors of Lymphoid Tissues (2008): \"Gray zone\" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma","volume":"2","author":"Hasserjian RP","year":"2009","unstructured":"Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, de Jong D, de Leval L. Commentary on the WHO Classification of Tumors of Lymphoid Tissues (2008): \"Gray zone\" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009, 2:89-95. 10.1007\/s12308-009-0039-7","journal-title":"J Hematop"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2000.01108.x","article-title":"The World Health Organization Classification of Malignant Lymphomas in Japan: incidence of recently recognized entities","volume":"50","author":"Lymphoma Study Group of Japanese Pathologists","year":"2000","unstructured":"Lymphoma Study Group of Japanese Pathologists. The World Health Organization Classification of Malignant Lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000, 50:696-702. 10.1046\/j.1440-1827.2000.01108.x","journal-title":"Pathol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens AM","year":"2021","unstructured":"Evens AM, Danilov A, Jagadeesh D, et al.. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021, 137:374-86. 10.1182\/blood.2020006926","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2501-1","article-title":"Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis","volume":"95","author":"Nie M","year":"2016","unstructured":"Nie M, Wang Y, Bi XW, et al.. Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis. Ann Hematol. 2016, 95:19-26. 10.1007\/s00277-015-2501-1","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie J","year":"2021","unstructured":"Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021, 137:743-50. 10.1182\/blood.2019004099","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100992","article-title":"Follicular lymphoma: the long and winding road leading to your cure?","volume":"57","author":"Gordon MJ","year":"2023","unstructured":"Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: the long and winding road leading to your cure?. Blood Rev. 2023, 57:100992. 10.1016\/j.blre.2022.100992","journal-title":"Blood Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346:235-42. 10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443332","article-title":"Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era","volume":"59","author":"Beygi S","year":"2018","unstructured":"Beygi S, Sadashiv S, Reilly JB, Khan C, Lister J. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era. Leuk Lymphoma. 2018, 59:2847-61. 10.1080\/10428194.2018.1443332","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard EJ","year":"2021","unstructured":"Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv. 2021, 5:2426-37. 10.1182\/bloodadvances.2021004665","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000253028","article-title":"Treatment-related Burkitt's lymphoma: literature review and case report of successful treatment with rituximab monotherapy","volume":"122","author":"Nagasaki A","year":"2009","unstructured":"Nagasaki A, Yamanoha A, Okudaira T, Miyagi T, Takasu N. Treatment-related Burkitt's lymphoma: literature review and case report of successful treatment with rituximab monotherapy. Acta Haematol. 2009, 122:211-5. 10.1159\/000253028","journal-title":"Acta Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/08880010500313298","article-title":"Refractoriness to rituximab monotherapy in a child with relapsed\/refractory Burkitt non-Hodgkin lymphoma","volume":"23","author":"Okur FV","year":"2006","unstructured":"Okur FV, Oguz A, Karadeniz C, Citak C, Poyraz A, Boyunaga O. Refractoriness to rituximab monotherapy in a child with relapsed\/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006, 23:25-31. 10.1080\/08880010500313298","journal-title":"Pediatr Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.903589","article-title":"Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile","volume":"56","author":"Tien YY","year":"2015","unstructured":"Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E. Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma. 2015, 56:65-71. 10.3109\/10428194.2014.903589","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"Hamlin PA","year":"2014","unstructured":"Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014, 19:1249-57. 10.1634\/theoncologist.2014-0113","journal-title":"Oncologist"},{"key":"ref15","article-title":"Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma","volume":"13","author":"Nakai S","year":"2005","unstructured":"Nakai S, Masaki T, Shintani T, et al.. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 2005, 13:1065-8.","journal-title":"Oncol Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.02.2012.5856","article-title":"Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation","volume":"2012","author":"Pircher A","year":"2012","unstructured":"Pircher A, Gassner EM, Steurer M, Wolf D. Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation. BMJ Case Rep. 2012, 2012:16-8. 10.1136\/bcr.02.2012.5856","journal-title":"BMJ Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195310000-00003","article-title":"Observations on the natural history of gastric cancer","volume":"226","author":"Meiselas LE","year":"1953","unstructured":"Meiselas LE. Observations on the natural history of gastric cancer. Am J Med Sci. 1953, 226:383-6. 10.1097\/00000441-195310000-00003","journal-title":"Am J Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07455-z","article-title":"Natural history of gastric cancer: observational study of gastric cancer patients not treated during follow-up","volume":"26","author":"Oh SY","year":"2019","unstructured":"Oh SY, Lee JH, Lee HJ, et al.. Natural history of gastric cancer: observational study of gastric cancer patients not treated during follow-up. Ann Surg Oncol. 2019, 26:2905-11. 10.1245\/s10434-019-07455-z","journal-title":"Ann Surg Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-012-0325-2","article-title":"Natural history of gastric cancer-a case followed up for eight years: early to advanced gastric cancer","volume":"5","author":"Fujisaki J","year":"2012","unstructured":"Fujisaki J, Nakajima T, Hirasawa T, et al.. Natural history of gastric cancer-a case followed up for eight years: early to advanced gastric cancer. Clin J Gastroenterol. 2012, 5:351-4. 10.1007\/s12328-012-0325-2","journal-title":"Clin J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-016-0680-5","article-title":"Twelve-year natural history of a gastric adenocarcinoma of fundic gland type","volume":"9","author":"Sato Y","year":"2016","unstructured":"Sato Y, Fujino T, Kasagawa A, et al.. Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. Clin J Gastroenterol. 2016, 9:345-51. 10.1007\/s12328-016-0680-5","journal-title":"Clin J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285892-long-term-recurrence-free-survival-of-an-elderly-patient-with-diffuse-large-b-cell-lymphoma-in-the-setting-of-rituximab-containing-therapy-and-a-natural-history-of-gastric-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T15:44:43Z","timestamp":1725032683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285892-long-term-recurrence-free-survival-of-an-elderly-patient-with-diffuse-large-b-cell-lymphoma-in-the-setting-of-rituximab-containing-therapy-and-a-natural-history-of-gastric-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.68217","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}